Polycythemia Vera (PV) is a rare condition characterized by the progressively increased number of red blood cells in the bloodstream, white blood cells (WBC) and platelets also increase in number in the affected people. This condition is known as myeloproliferative neoplasms, where the body produces too many of these cells (RBC, WBC and Platelets). These new cells cause the blood to be thicker than usual, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins, deep in the arms and the legs, it is known as deep vein thrombosis (DVT). Mutation in the JAK2 kinase is responsible for PV. Most cases of PV are associated with genetic changes that are somatic, not in the egg and sperm cells, which pass on genetic information to offspring.
The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2. Bone marrow aspiration and biopsy are also done to confirm whether or not a person has PV. The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets.
Get FREE sample copy at:
The Polycythemia Vera market report also covers emerging drugs, current treatment practices, Polycythemia Vera market share of the individual therapies, current and forecasted Polycythemia Vera Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Polycythemia Vera treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Polycythemia Vera Market Key Facts
The total prevalent population of Polycythemia Vera (PV) in the 7MM was found to be 301,833 in 2017.
Most of the diagnosed prevalence of PV was found in the United States with 107,760 cases in 2017.
Among the European 5 countries, Germany had the highest diagnosed prevalent population of PV with 12,085 cases, followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population of 7,334 in 2017. Japan had 22,974 diagnosed prevalent cases for PV in 2017.
A higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM countries.
Key Benefits of Polycythemia Vera Market Report
Polycythemia Vera market report provides an in-depth analysis of Polycythemia Vera Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Polycythemia Vera market report will help in developing business strategies by understanding the Polycythemia Vera Market trends & developments, key players and future market competition that will shape and drive the Polycythemia Vera market in the upcoming years.
The Polycythemia Vera market report covers Polycythemia Vera current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Polycythemia Vera market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Polycythemia Vera market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Polycythemia Vera market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Polycythemia Vera market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
According to DelveInsight’s epidemiology model for PV, based on phenotypes of the disease, suggests that of the total PV cases in the 7MM, varied significantly among different countries. Highest diagnosed cases were found in the US whereas in European countries, Germany had the highest prevalent cases of PV. Most of the diagnosed cases were found in males, in comparison to females in all 7MM.
The Polycythemia Vera epidemiology section covers insights about historical and current Polycythemia Vera patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Polycythemia Vera Drugs Uptake and Key Market Players
The Polycythemia Vera Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched in the market during the study period. The analysis covers Polycythemia Vera market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Owing to the launch of upcoming therapies, the market size of Polycythemia Vera is expected to increase during the forecast period (2020-2030). Some of the Key players in the Polycythemia Vera market includes:
AOP Orphan Pharmaceuticals AG
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Polycythemia Vera Competitive Intelligence Analysis
4. Polycythemia Vera Market Overview at a Glance
5. Polycythemia Vera Disease Background and Overview
6. Polycythemia Vera Patient Journey
7. Polycythemia Vera Epidemiology and Patient Population
8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices
9. Polycythemia Vera Unmet Needs
10. Key Endpoints of Polycythemia Vera Treatment
11. Polycythemia Vera Marketed Products
12. Polycythemia Vera Emerging Therapies
13. Polycythemia Vera Seven Major Market Analysis
14. Attribute Analysis
15. Polycythemia Vera Market Outlook (7 major markets)
16. Polycythemia Vera Access and Reimbursement Overview
17. KOL Views on the Polycythemia Vera Market.
18. Polycythemia Vera Market Drivers
19. Polycythemia Vera Market Barriers
21. DelveInsight Capabilities
DelveInsight’s ‘Polycythemia Vera – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Polycythemia Vera Pipeline Insight, 2020 report by DelveInsight outlays detailed insights of present clinical development scenario and growth prospects.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States